FIELD: biotechnology.
SUBSTANCE: disclosed are immune cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular domain, a transmembrane domain and an intracellular domain comprising a costimulatory endodomain, wherein the costimulatory endodomain comprises an intracellular signalling domain of 4-1BB/CD137 and five additional amino acids. Extracellular domain of CAR contains an antigen-binding domain specifically binding to glypican-3. Also disclosed are nucleic acids, vectors, compositions and methods of treating cancer using engineered immune cells containing CAR.
EFFECT: invention provides improved effectiveness of CAR-T and can be used for treating certain types of cancer.
49 cl, 19 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELL | 2015 |
|
RU2768019C2 |
| HLA-DR-BINDING CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELL | 2019 |
|
RU2778890C1 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CHIMERIC ANTIGEN RECEPTORS AND THEIR PRODUCTION METHODS | 2015 |
|
RU2753965C2 |
| SIGNAL SYSTEM | 2015 |
|
RU2731638C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2832516C2 |
